MedTrace Logo

Study of the Electrocardiographic Effects of TA-8995

NCT02241759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2015-02-16

No results posted yet for this study

Summary

A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.

Conditions

  • Dyslipidaemia

Interventions

DRUG

TA-8995

DRUG

Moxifloxacin

DRUG

Placebo

Sponsors & Collaborators

  • Xention Ltd

    lead INDUSTRY

Principal Investigators

  • Ashley Brooks · Covance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02241759 on ClinicalTrials.gov